VivoSeq
Other

Noise-Induced Hearing Loss

7

Pipeline Programs↗

0

Active Trials↗

6

Companies Involved↗

Noise-Induced Hearing Loss is an early-stage landscape with 7 programs across 6 companies. The most active players are Azurity Pharmaceuticals, Pfizer, Edison Pharmaceuticals Inc. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

50/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Azurity Pharmaceuticals

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 1E

Edison Pharmaceuticals Inc

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2F

Fresenius Kabi Oncology Ltd.

1 program

ApprovedJohnson & Johnson logo

Johnson & Johnson

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

8

clinical trials

Completed4 · 50%
Terminated3 · 38%
Withdrawn1 · 13%

Clinical Trials

Trial Activity

8 trials

Protective Effects of EPI-743 on Noise-Induced Hearing Loss
Completed·EEdison Pharmaceuticals Inc·Phase 2·NCT02257983·77 enrolled
Improvement of Tinnitus After Oral Zinc on Patients With Noise-induced Hearing Loss
Completed·—·N/A·NCT02951715·20 enrolled
Antioxidation Medication for Noise-induced Hearing Loss
Completed·NNational Taiwan University Hospital·Phase 2·NCT00552786·53 enrolled
Micronutrients to Prevent Noise-induced Hearing Loss
Completed·UUniversity of Michigan·Phase 2·NCT00808470·72 enrolled
Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)
Terminated·WWashington University School of Medicine·Phase 2·NCT04774250·3 enrolled
Noise-Induced Hearing Loss-Acute Exposure Treatment
Terminated·WWashington University School of Medicine·Phase 2·NCT04768569·24 enrolled
Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL)
Terminated·SSouthern Illinois University·Phase 3·NCT02903355·351 enrolled
Prevention of Noise-induced Hearing Loss
Withdrawn·WWashington University School of Medicine·Phase 1/2·NCT02049073

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)